The share of global drug sales under patent protection is projected to fall from 12% to 4% by 2030. Sandoz is buying pipeline to meet it.
Triple-negative breast tumours recruit immune cells to release a nerve growth signal, then grow their own nerve supply. An approved drug blocks that signal.
Three mutations and two deletions spreading fast in Uganda, blunting the frontline malaria combination. One gene appears to reduce response to both drugs at once — which is not how combination therapy is supposed to fail.
There has been no human Lyme vaccine for two decades — one was withdrawn in 2002 amid safety claims never substantiated. A 9,437-person Phase 3 now sits with the EMA.
Amyloid imaging shows whether Alzheimer’s pathology is present. Tau imaging shows how far it has spread — and tau tracks with symptoms in a way amyloid does not.
Older ankles are stiffer because opposing muscles tense against each other. That buys stability and costs the springy push-off that makes walking cheap.
Two things people can actually change, measured in midlife, tracked against cognition years later. The association is real; the causal claim is not established.
A foxglove extract used since the eighteenth century, at less than 10 cents a day, cut heart-failure hospitalisations by about a quarter in a modern randomised trial.
The second company this year to bet on post-bariatric hypoglycaemia — and it is taking a completely different mechanistic route to the same problem.
Blood bicarbonate rose about 7% across two decades of NHANES data while atmospheric CO2 went from 369 to over 420 ppm. The researchers are explicit that two trends moving together is not causation.
Isotope labelling traced what gut bacteria actually eat when fibre runs short. The answer is the mucus layer protecting your intestinal wall — and the byproducts are toxic.
Thousands of independent primary-care practices sit outside insurance networks, unreachable by employers one contract at a time. Aligned aggregates them under one agreement.